Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2021 07:30 ET | Source: ContraFect Corporation

ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update

YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
November 09, 2021 07:30 ET | Source: ContraFect Corporation

ContraFect’s New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis

YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
August 25, 2020 07:30 ET | Source: ContraFect Corporation

ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation

YONKERS, New York, Aug. 25, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
May 15, 2020 07:30 ET | Source: ContraFect Corporation

ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update

YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
May 11, 2020 07:30 ET | Source: ContraFect Corporation

ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book

YONKERS, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...